PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Free Report) CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the transaction, the chief financial officer now owns 107,991 shares in the company, valued at $6,161,966.46. The trade was a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
PROCEPT BioRobotics Stock Up 1.4 %
Shares of NASDAQ PRCT traded up $0.77 during mid-day trading on Wednesday, reaching $57.80. The company had a trading volume of 517,627 shares, compared to its average volume of 724,050. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The company has a market capitalization of $3.17 billion, a price-to-earnings ratio of -29.64 and a beta of 1.05. The stock has a fifty day moving average of $68.87 and a two-hundred day moving average of $78.75. PROCEPT BioRobotics Co. has a 12-month low of $45.56 and a 12-month high of $103.81.
PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million. As a group, equities research analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.
Institutional Trading of PROCEPT BioRobotics
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the company. Wells Fargo & Company reissued an “overweight” rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Truist Financial reissued a “buy” rating and issued a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Finally, Morgan Stanley reduced their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics has an average rating of “Moderate Buy” and a consensus target price of $94.29.
Check Out Our Latest Analysis on PRCT
PROCEPT BioRobotics Company Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
See Also
- Five stocks we like better than PROCEPT BioRobotics
- What is the MACD Indicator and How to Use it in Your Trading
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- What Are Earnings Reports?
- Alphabet’s Officially In A Bear Market—Time To Buy?
- ESG Stocks, What Investors Should Know
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.